Jazz Pharmaceuticals has appointed Renee Galá, its current president and chief operating officer, as the next CEO effective August 11, 2025. Galá succeeds co-founder Bruce Cozadd, who plans to retire after leading the company for nearly two decades. This leadership change marks a strategic evolution for Jazz, aiming to leverage Galá’s operational expertise to guide the company’s growth and innovation trajectory in the biopharma sector.